Helix BioPharma Corp. Announces Fiscal Q3 2010 Results


    


    
</pre>
<p>AURORA, Ontario, <span class="xn-chron">June 11</span> /CNW/ -- Helix BioPharma Corp. (TSX, FSE: HBP / Pink Sheets:   HXBPF) today announced financial results for the third quarter ended <span class="xn-chron">April 30, 2010</span>.</p>
<pre>
    

    HIGHLIGHTS

    --  Announced on February 12, 2010 positive preliminary primary endpoint
        findings from the ongoing Phase II pharmacokinetic clinical study of
        Topical Interferon Alpha-2b for its lead indication in patients with
        low-grade cervical lesions.

    --  Announced on June 8, 2010 that its Phase II trial of Topical
Interferon
        Alpha-2b for its secondary indication of the treatment of ano-genital
        warts (AGW) showed that the treatment and placebo preparations were
        well tolerated, but the treatment did not show a statistically
        significant effect in the primary and secondary efficacy analyses.

    RESULTS FROM OPERATIONS
    
</pre>
<p>Three and nine month periods ended <span class="xn-chron">April 30, 2010</span> compared to the same period in the previous year</p>
<pre>
    

    Loss for the period
    
</pre>
<p>The Company recorded a loss of <span class="xn-money">$4,200,000</span> and <span class="xn-money">$11,348,000</span>, respectively for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> for a loss per common share of <span class="xn-money">$0.07</span> and <span class="xn-money">$0.19</span>, respectively. In the comparative three and nine month periods ended <span class="xn-chron">April 30, 2009</span>, the Company recorded a loss of <span class="xn-money">$4,134,000</span> and <span class="xn-money">$10,707,000</span> respectively, for a loss per common share of <span class="xn-money">$0.08</span> and <span class="xn-money">$0.21</span>, respectively.</p>
<pre>
    

    Revenues
    
</pre>
<p>Revenues totaled <span class="xn-money">$1,114,000</span> and <span class="xn-money">$3,255,000</span> respectively for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> and represent an increase of <span class="xn-money">$190,000</span> (20.6%) and <span class="xn-money">$349,000</span> (12.0%) when compared to the three and nine month periods ended <span class="xn-chron">April 30, 2009</span>.</p>
<p/>
<p>Product revenues totaled <span class="xn-money">$933,000</span> and <span class="xn-money">$2,848,000</span> respectively for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> and represent an increase of <span class="xn-money">$140,000</span> (17.7%) and <span class="xn-money">$394,000</span> (16.1%) when compared to the three and nine month periods ended <span class="xn-chron">April 30, 2009</span>.  For the three month period ended <span class="xn-chron">April 30, 2010</span>, the majority of the product revenue increase is represented by the combined sales of Monovisc(TM) and Orthovisc®. For the nine month period ended <span class="xn-chron">April 30, 2010</span>, while there were sales increases for both Imunovir(TM) and Klean-Prep®, the majority of the product revenue increase is represented by the combined sales of Monovisc(TM) and Orthovisc®.  The Company commenced distribution of Monovisc(TM) in <span class="xn-location">Canada</span> during the fiscal first quarter of 2010.</p>
<p/>
<p>License fees and royalties totaled <span class="xn-money">$181,000</span> and <span class="xn-money">$407,000</span> respectively for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> and represent an increase of <span class="xn-money">$50,000</span> (38.2%) and a decrease of <span class="xn-money">$45,000</span> (10.0%) when compared to the three and nine month periods ended <span class="xn-chron">April 30, 2009</span>. The increase in license fees and royalties for the three month period ended <span class="xn-chron">April 30, 2010</span> reflects additional royalty revenues resulting from a royalty audit of Helsinn-Birex, the licensee of the Company's Klean-Prep® technology outside of <span class="xn-location">Canada</span>.  The decrease for the nine month period ended <span class="xn-chron">April 30, 2010</span> in license fees and royalty revenues reflects a US$75,000 termination payment from Lumera Corporation ("Lumera") in the first quarter of fiscal 2009.  Excluding the Lumera termination payment, license fees and royalty revenues are comprised solely of royalties related to sales of Klean-Prep® outside of <span class="xn-location">Canada</span>.</p>
<pre>
    

    Cost of sales and margins
    
</pre>
<p>Cost of sales totaled <span class="xn-money">$400,000</span> and <span class="xn-money">$1,279,000</span> respectively for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> (three and nine month periods ended <span class="xn-chron">April 30, 2009</span> were <span class="xn-money">$375,000</span> and <span class="xn-money">$1,160,000</span> respectively).  Margins, on a percentage basis, for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> were 57.1% and 55.1% (three and nine month periods ended <span class="xn-chron">April 30, 2009</span> were 52.7% and 52.7% respectively).  The increase in margins reflects higher margins on the sales of Monovisc(TM).</p>
<pre>
    

    Research & development
    
</pre>
<p>Research and development costs for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> totaled <span class="xn-money">$3,142,000</span> and <span class="xn-money">$8,402,000</span> respectively (three and nine month periods ended <span class="xn-chron">April 30, 2009</span> were <span class="xn-money">$3,082,000</span> and <span class="xn-money">$7,584,000</span> respectively).  Research and development expenditures associated with the ongoing Topical Interferon Alpha-2b studies reflect the majority of the increase in the quarter and were offset by an investment tax credit which was realized by the Company.  L-DOS47 research and development expenditures for the three month period ended <span class="xn-chron">April 30, 2010</span> were flat when compared to the three month period ended <span class="xn-chron">April 30, 2009</span>.  For the nine month period ended <span class="xn-chron">April 30, 2010</span> the investment tax credits realized by the Company, were offset by higher research and development expenditures associated with the Company's L-DOS47 drug product candidate along with a marginal increase in research and development expenditures associated with Topical Interferon Alpha-2b and various other general research and development expenditures.</p>
<p/>
<p>Both of the Company's clinical programs associated with Topical Interferon Alpha-2b were in the late stages of completion during the quarter ended <span class="xn-chron">April 30, 2010</span>, resulting in lower clinical research expenditures for the three month period ended <span class="xn-chron">April 30, 2010</span>.  The lower clinical research expenditures were offset by higher consulting services and scale-up contract manufacturing initiatives in preparation of a U.S. Phase II/III IND and European Phase III CTA filing for low-grade cervical lesions.  For the nine month period ended <span class="xn-chron">April 30, 2010</span>, consulting services and clinical research expenditures represent the bulk of higher research and development expenditures associated with Topical Interferon Alpha-2b.</p>
<p/>
<p>For the three month period ended <span class="xn-chron">April 30, 2010</span>, L-DOS47 research and development expenditures were flat when compared to the three month period ended <span class="xn-chron">April 30, 2009</span>.  Lower contract manufacturing expenditures were offset by higher collaborative scientific expenditures and clinical research expenditures in anticipation of U.S. Phase I IND and Polish Phase I/II CTA filings.  For the nine month period ended <span class="xn-chron">April 30, 2010</span>, collaborative scientific expenditures and clinical research expenditures represent the bulk of the increase in L-DOS47 research and development expenditures.</p>
<p/>
<p>The Company has extended its anticipated timing of filing its IND and CTA for L-DOS47 slightly, from the end of the fourth quarter of fiscal 2010 to mid-to-late first quarter of fiscal 2011.  The extension results from a delay in commencing the necessary GLP animal toxicology studies due to third party scheduling availability.  The filings remain subject to successful and timely completion of the remaining pre-IND activities, primarily the GLP animal toxicology studies and stability testing of the L-DOS47 clinical batch.</p>
<pre>
    

    Operating, general & administration
    
</pre>
<p>Operating, general and administration expenses for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> totaled <span class="xn-money">$779,000</span> and <span class="xn-money">$2,225,000</span> respectively (three and nine month periods ended <span class="xn-chron">April 30, 2009</span> were <span class="xn-money">$1,021,000</span> and <span class="xn-money">$3,127,000</span> respectively).  The decrease in operating, general and administration expenditures for the three month period ended <span class="xn-chron">April 30, 2010</span> is mainly the result of higher costs in the prior year associated with the filing of a Form 20-F registration statement with the SEC which became effective during the third quarter of fiscal 2009.  For the nine month period ended <span class="xn-chron">April 30, 2010</span>, the decrease in operating, general and administrative expenditures mainly reflects lower investor and media relations expenditures and associated marketing materials and expenditures incurred in the prior year associated with consulting services which have since been terminated, the SEC registration statement filing and the implementation of a new financial reporting system.</p>
<pre>
    

    Sales and marketing
    
</pre>
<p>Sales and marketing expenses for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> totaled <span class="xn-money">$303,000</span> and <span class="xn-money">$862,000</span> respectively (three and nine month periods ended <span class="xn-chron">April 30, 2009</span> were <span class="xn-money">$210,000</span> and <span class="xn-money">$727,000</span> respectively).  For the three and nine month periods ended <span class="xn-chron">April 30, 2010</span>, the increase in sales and marketing expenditures is the result of increased sales commissions as well as marketing and promotion activities and quality compliance expenditures associated with the product launch of Monovisc(TM) in <span class="xn-location">Canada</span>.</p>
<pre>
    

    Amortization of intangible and capital assets
    
</pre>
<p>Amortization of intangible assets for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> totaled $nil and $nil respectively (three and nine month periods ended <span class="xn-chron">April 30, 2009</span> were <span class="xn-money">$3,000</span> and <span class="xn-money">$9,000</span> respectively).  Management determined the carrying value of intangible assets was impaired and wrote down the balance at <span class="xn-chron">July 31, 2009</span>.  Amortization of capital assets for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> totaled <span class="xn-money">$112,000</span> and <span class="xn-money">$317,000</span> respectively (three and nine month periods ended <span class="xn-chron">April 30, 2009</span> were <span class="xn-money">$64,000</span> and <span class="xn-money">$191,000</span> respectively).</p>
<pre>
    

    Stock-based compensation
    
</pre>
<p>Stock-based compensation expense for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> totalled <span class="xn-money">$251,000</span> and <span class="xn-money">$1,016,000</span> respectively (three and nine month periods ended <span class="xn-chron">April 30, 2009</span> were <span class="xn-money">$234,000</span> and <span class="xn-money">$865,000</span> respectively).  The stock-based compensation expense in fiscal 2010 relates to the ongoing amortization of compensation costs of stock options granted on <span class="xn-chron">December 17, 2008</span>, and <span class="xn-chron">December 14, 2009</span>, respectively over their vesting period.</p>
<pre>
    

    Interest income
    
</pre>
<p>Interest income for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> totaled <span class="xn-money">$13,000</span> and <span class="xn-money">$37,000</span> respectively (three and nine month periods ended <span class="xn-chron">April 30, 2009</span> were <span class="xn-money">$27,000</span> and <span class="xn-money">$332,000</span> respectively). The decrease in interest income in fiscal 2010 reflects lower interest rates earned on deposits and lower cash balances.</p>
<pre>
    

    Foreign exchange gain/loss
    
</pre>
<p>Foreign exchange losses for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> totaled <span class="xn-money">$326,000</span> and <span class="xn-money">$514,000</span> respectively (three and nine month periods ended <span class="xn-chron">April 30, 2009</span> were losses of <span class="xn-money">$67,000</span> and a loss of <span class="xn-money">$199,000</span> respectively).  Foreign exchange losses are mainly the result of the foreign currency translation of the Company's integrated foreign operation in <span class="xn-location">Ireland</span>, cash balances as well as a value added tax receivable, all of which are denominated in Euro dollars.  In the three month period ended <span class="xn-chron">April 30, 2010</span> the Euro dollar has materially depreciated against the Canadian dollar.</p>
<pre>
    

    Income taxes
    
</pre>
<p>Income tax expense for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> totaled <span class="xn-money">$14,000</span> and <span class="xn-money">$25,000</span> respectively (three and nine month periods ended <span class="xn-chron">April 30, 2009</span> were <span class="xn-money">$29,000</span> and <span class="xn-money">$83,000</span> respectively).  All income taxes are attributable to the Company's operations in <span class="xn-location">Ireland</span>.</p>
<pre>
    

    cash flow

    Operating activities
    
</pre>
<p>Cash used in operating activities for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> totaled <span class="xn-money">$3,702,000</span> and <span class="xn-money">$9,148,000</span> respectively, including a net loss of <span class="xn-money">$4,200,000</span> and <span class="xn-money">$11,348,000</span> respectively. Cash used in operating activities for the three and nine month periods ended <span class="xn-chron">April 30, 2009</span> totaled <span class="xn-money">$3,555,000</span> and <span class="xn-money">$8,429,000</span> respectively, including a net loss of <span class="xn-money">$4,134,000</span> and <span class="xn-money">$10,707,000</span> respectively.</p>
<p/>
<p>Significant adjustments for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> include amortization of capital assets of <span class="xn-money">$112,000</span> and <span class="xn-money">$317,000</span> respectively (2009 - <span class="xn-money">$64,000</span> and <span class="xn-money">$191,000</span>), amortization of intangible assets of $nil and $nil respectively (2009 - <span class="xn-money">$3,000</span> and <span class="xn-money">$9,000</span>), deferred lease credits of <span class="xn-money">$6,000</span> and <span class="xn-money">$19,000</span> (2009 - $nil and $nil), stock-based compensation related to earlier stock option grants of <span class="xn-money">$251,000</span> and <span class="xn-money">$1,016,000</span> respectively (2009 - <span class="xn-money">$234,000</span> and <span class="xn-money">$865,000</span>), foreign exchange losses of <span class="xn-money">$326,000</span> and <span class="xn-money">$514,000</span> respectively (2009 - <span class="xn-money">$67,000</span> and <span class="xn-money">$199,000</span> respectively) and changes in non-cash working capital balances related to operations of negative <span class="xn-money">$185,000</span> and <span class="xn-money">$372,000</span> (2009 - <span class="xn-money">$211,000</span> and <span class="xn-money">$1,014,000</span>).</p>
<pre>
    

    Financing activities
    
</pre>
<p>Financing activities for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> totaled <span class="xn-money">$140,000</span> and <span class="xn-money">$11,737,000</span> respectively (three and nine month periods ended <span class="xn-chron">April 30, 2009</span> were $nil and <span class="xn-money">$9,659,000</span> respectively).  Financing activities for the three month period ended <span class="xn-chron">April 30, 2010</span> reflect proceeds from the exercise of stock options.  For the nine month period ended <span class="xn-chron">April 30, 2010</span> and 2009, other than the proceeds from the exercise of stock options, financing activities also included the net proceeds of two separate private placements.</p>
<pre>
    

    Investing activities
    
</pre>
<p>Use of cash in investing activities for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> totaled <span class="xn-money">$104,000</span> and <span class="xn-money">$588,000</span> respectively (three and nine month periods ended <span class="xn-chron">April 30, 2009</span> were <span class="xn-money">$416,000</span> and <span class="xn-money">$490,000</span> respectively) and represents capital acquisitions in both fiscal periods.</p>
<pre>
    

    Liquidity and Capital Resources

    
</pre>
<p>Since inception, the Company has financed its operations from public and private sales of equity, the exercise of warrants and stock options, and, to a lesser extent, interest income from funds available for investment, government grants, investment tax credits, and revenues from distribution, licensing and contract services. Since the Company does not have net earnings from its operations, the Company's long-term liquidity depends on its ability to access the capital markets, which depends substantially on the success of the Company's ongoing research and development programs.</p>
<p/>
<p>At <span class="xn-chron">April 30, 2010</span>, the Company had cash and cash equivalents totaling <span class="xn-money">$15,981,000</span> (<span class="xn-chron">July 31, 2009</span> - <span class="xn-money">$14,494,000</span>).  The increase in cash and cash equivalents in fiscal 2010 is the result of a private placement completed on <span class="xn-chron">September 8, 2009</span> where the Company issued 6,625,000 units at <span class="xn-money">$2.05</span> per unit, for gross proceeds of <span class="xn-money">$13,581,250</span>.  The total number of common shares issued as at <span class="xn-chron">April 30, 2010</span> was 59,870,335 (<span class="xn-chron">July 31, 2009</span> - 53,175,335).</p>
<p>At <span class="xn-chron">April 30, 2010</span>, the Company's working capital was <span class="xn-money">$16,411,000</span> (<span class="xn-chron">July 31, 2009</span> - <span class="xn-money">$15,296,000</span>).</p>
<p/>
<p>Based on our planned expenditures and assuming no material unanticipated expenses, our forecasts indicate that our cash reserves and expected cash from operations will be sufficient to meet our anticipated cash needs for working capital and capital expenditures to the end of <span class="xn-chron">September 2011</span>.  These planned expenditures do not include those necessary to conduct the proposed U.S. Phase I and Polish Phase I/II clinical trials for L-DOS47 or the proposed U.S. Phase II/III and European Phase III clinical trials for Topical Interferon Alpha-2b (low-grade cervical lesions).  As stated above, these trials will require substantial funding beyond the Company's current resources.</p>
<p/>
<p>The Company will continue to seek additional funding to carry out its business plan and to minimize risks to its operations.  Equity financing has historically been Helix's primary source of funding, however, the market for equity financings for companies such as Helix is challenging, and the global economic downturn and credit crisis have added further challenges. There can be no assurance that additional funding by way of equity financing will be available.  Any additional equity financing, if secured, may result in significant dilution to the existing shareholders at the time of such financing.  The Company may also seek additional funding from other sources, including technology licensing, co-development collaborations, and other strategic alliances, which, if obtained, may reduce the Company's interest in its projects or products.  There can be no assurance, however, that any alternative sources of funding will be available.  The failure of the Company to obtain additional funding on a timely basis may result in the Company reducing, delaying or cancelling one or more of its planned research, development and marketing programs and reducing related personnel, any of which could impair the current and future value of the business. It may also have a material adverse effect on the Company's ability to continue as a going concern.</p>
<p/>
<p>The Company's unaudited interim consolidated balance sheet as at <span class="xn-chron">April 30, 2010</span> and the audited consolidated balance sheet as at <span class="xn-chron">July 31, 2009</span> are summarized below:</p>
<pre>
    


    
</pre>
<p> </p>
<pre>
    
    Consolidated Balance Sheets as at
    ($ thousands)
    
</pre>
<p> </p>
<pre>
    
                          30-Apr 31-Jul                   30-Apr 31-Jul
                            2010   2009                     2010   2009
                            ----   ----                     ----   ----
                                        Current
    Current assets:                     liabilities:
      Cash and cash
       equivalents        15,981 14,494  Accounts payable  1,074  1,299
                                         Accrued
      Accounts receivable    995  1,053   liabilities        692    834
                                         Deferred lease
      Inventory              748    858   credit              25     25
                                                             ---    ---
      Prepaid and other      478  1,049                    1,791  2,158
    
</pre>
<p> </p>
<p> </p>
<pre>
    
                          18,202 17,454
                                        Non current
                                        liabilities           79     98
    
</pre>
<p> </p>
<pre>
    
                                        Shareholders'
    Non current assets     2,141  1,865 equity            18,473 17,063
                           -----  -----                   ------ ------
    
</pre>
<p> </p>
<pre>
    
                          20,343 19,319                   20,343 19,319
                          ====== ======                   ====== ======



    
</pre>
<p>The Company's unaudited interim consolidated statements of operations and cash flows for the three and nine month periods ended <span class="xn-chron">April 30, 2010</span> and 2009 are summarized below:</p>
<pre>
    



    
</pre>
<p> </p>
<pre>
    
    Consolidated Statements of Operations
    for the three and nine month periods ended April 30, 2010 and 2009
    ($ thousands, except for per share data)
    
</pre>
<p> </p>
<pre>
    
                                 Three months        Nine months
                                 ended April
                                                    30          ended April 30
                                 2010     2009      2010      2009
                                 ----     ----      ----      ----
    Revenue:
      Product revenue             933      793     2,848     2,454
      License fees &
       royalties                  181      131       407       452
                                  ---      ---       ---       ---
                                1,114      924     3,255     2,906
    
</pre>
<p> </p>
<pre>
    
    Expenses:
      Cost of sales             400      375     1,279     1,160
      Research and
       development            3,142    3,082     8,402     7,584
      Operating,
       general and
       admin                    779    1,021     2,225     3,127
      Sales and
       marketing                303      210       862       727
      Amortization of
       intangible
       assets                     -        3         -         9
      Amortization of
       capital assets           112       64       317       191
      Stock-based
       compensation             251      234     1,016       865
      Interest income,
       net                      (13)     (27)      (37)     (332)
      Foreign exchange
       loss                     326       67       514       199
                                ---      ---       ---       ---
                              5,300    5,029    14,578    13,530
    Loss before
     income taxes            (4,186)  (4,105)  (11,323)  (10,624)
    
</pre>
<p> </p>
<pre>
    
    Income taxes                 14       29        25        83
                                ---      ---       ---       ---
    
</pre>
<p> </p>
<pre>
    
    Loss for the
     period                  (4,200)  (4,134)  (11,348)  (10,707)
                             ======   ======   =======
    
</pre>
<p> </p>
<p> </p>
<pre>
    
                  Loss per
                  share:
                     Basic    (0.07)   (0.08)    (0.19)    (0.21)
                     Diluted  (0.07)   (0.08)    (0.19)    (0.21)




    
</pre>
<p> </p>
<pre>
    
    Consolidated Statements of Cash Flows
    for the three and nine month periods ended April 30, 2010 and 2009
    ($thousands)
    
</pre>
<p> </p>
<pre>
    
                                      Three months              Nine months
                                       ended April
                                                 30           ended April 30
                                     2010      2009           2010       2009
                                     ----      ----           ----       ----
    
</pre>
<p> </p>
<pre>
    
    Cash provided by (used
     in):
      Loss for the period          (4,200)   (4,134)       (11,348)   (10,707)
    
</pre>
<p> </p>
<pre>
    
      Items not involving
       cash:
        Amortization of capital
         assets                       112        64            317        191
        Amortization of
         intangibles                    -         3              -          9
        Deferred lease credit          (6)        -            (19)         -
        Stock-based
         compensation                 251       234          1,016        865
        Foreign exchange loss         326        67            514        199
                                      ---       ---            ---        ---
                                   (3,517)   (3,766)        (9,520)    (9,443)
    
</pre>
<p> </p>
<pre>
    
    Change in non-cash
     working capital                 (185)      211            372      1,014
                                     ----       ---            ---      -----
    Operating activities           (3,702)   (3,555)        (9,148)    (8,429)
    
</pre>
<p> </p>
<p>Financing activities              140         -         11,737      9,659</p>
<p> </p>
<pre>
    
    Investing activities             (104)     (416)          (588)      (490)
    Effect of exchange rate
     changes
      on cash and cash
       equivalents                   (326)      (67)          (514)      (199)
                                     ----       ---           ----       ----
    
</pre>
<p> </p>
<pre>
    
    Increase in cash               (3,992)   (4,038)         1,487        541
    Cash:
      Beginning of the period      19,973    23,636         14,494     19,057
                                   ------    ------         ------     ------
      End of the period            15,981    19,598         15,981     19,598
                                   ======    ======         ======     ======




    
</pre>
<p>The Company's unaudited interim consolidated financial statements and management's discussion and analysis of financial condition and results of operations are being filed today with Canadian securities regulatory authorities and will be available at SEDAR at <a href="http://www.sedar.com">www.sedar.com</a>.</p>
<pre>
    

    About Helix BioPharma Corp.
    
</pre>
<p>Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha- 2b. Helix is listed on the TSX and FSE under the symbol "HBP" and the OTCQX International Market under the symbol "HXBPF".</p>
<p/>
<p> </p>
<p> </p>
<pre>
    
    For further information contact:
                  Investor Relations
                  Robert Flamm, Ph.D.
                  Russo Partners LLC
                  Tel: (212) 845-4226
                  Email:  robert.flamm@russopartnersllc.com
                  www.russopartnersllc.com


    Forward-Looking Statements and Risks and Uncertainties
    
</pre>
<p>This News Release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements"), within the meaning of applicable securities laws, regarding the Company's development of its L-DOS47 and Topical Interferon Alpha-2b new drug candidates; sufficiency of the Company's cash reserves and expected cash from operations; the Company's plans to seek funding;  the Company's expected timing of filing its IND and CTA for L-DOS47, and other information in future periods. Forward-looking statements, including financial outlooks, are intended to provide information about management's current plans and expectations regarding future operations, including but not limited to, future financing requirements, and may not be appropriate for other purposes. Certain material factors or assumptions which have been applied in making forward-looking statements, include, but are not limited to, future revenue and expenditures; the safety and efficacy of the Company's drug candidates; the timely and successful completion of the remaining pre-IND activities for L-DOS47, and the receipt of required regulatory approvals and necessary financing.  Important risk factors that could cause actual results to differ materially from these forward-looking statements include, without limitation, the Company's continuing need for additional capital, which may not be available in a timely manner or at all; uncertainty whether L-DOS47 or Topical Interferon Alpha-2b will be successfully developed and commercialized; the need for further regulatory approvals, which are not assured; the Company's dependence on performance by its third party providers of intellectual property, services and supplies, including supplies of drug product; uncertainty whether any of the Company's planned or future clinical trials will be approved, conducted or achieve expected results; product liability and insurance risks; uncertainties related to research and development, including manufacturing risks;  intellectual property risks; uncertainties regarding future expenses and revenue; uncertainties related to economic conditions; and the risk of changes in business strategy or development plans. Investors should consult the Company's quarterly and annual filings, including its latest Form 20-F, with the Canadian and U.S. securities commissions at <a href="http://www.sedar.com">www.sedar.com</a> and at <a href="http://www.sec.gov/edgar.shtml">www.sec.gov/edgar.shtml</a> for additional information on these and other risks and uncertainties which may affect the Company. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.</p>
<pre>
    




    

For further information: For further information: Investor Relations, Robert Flamm, Ph.D., Russo Partners LLC, +1-212-845-4226, robert.flamm@russopartnersllc.com

Organization Profile

HELIX BIOPHARMA CORP.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890